Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Seagen Inc.
Molecular Templates, Inc.
Barbara Ann Karmanos Cancer Institute
Sanofi